Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AUTO 3

Next Previous
X
Search
Drug Profile

AUTO 3

Alternative Names: Anti-CD19-anti-CD22 CAR T Cell therapy; AUTO 3NG; AUTO3; CD19/22 CAR T cells

Latest Information Update: 19 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University College London
  • Developer Autolus
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Diffuse large B cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 06 Dec 2023 Autolus completes a Phase-I/II development in Diffuse large B cell lymphoma (Second-line therapy or greater, Combination therapy, Monotherapy) in USA and United Kingdom (IV) (NCT03287817) (EudraCT2016-004682-11)
  • 06 Jan 2021 AUTO 3 is available for licensing as of 06 Jan 2021. https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-provides-business-outlook-2021-2022
  • 07 Dec 2020 Interim efficacy and adverse events data from a phase I/II ALEXANDER trial in diffuse large B cell lymphoma released by Autolus Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top